When Sepsis Triggers a Dangerous Heart Rhythm, Doctors Are Still Treating Without a Map

Sepsis sends millions of patients into intensive care units every year, and for a substantial fraction of them, a second crisis begins to unfold almost as soon as the first is recognized. Between 9 percent and 20 percent of patients hospitalized with sepsis—the life-threatening, dysregulated response of the body to infection—develop new-onset atrial fibrillation, an irregular and often rapid rhythm of the heart’s upper chambers that emerges under the extreme physiological stress of critical illness. The arrhythmia is not a passing curiosity of the intensive care monitor. It is linked to higher risks of stroke, death, and later recurrence, and yet, despite how frequently it appears at the bedside, clinicians who encounter it have no disease-specific guidelines to guide their decisions. Much of what is known about this condition still sits alongside what remains genuinely unclear, and that gap between evidence and practice is now the focus of a comprehensive effort to map the field.

A new review published online in the Journal of Intensive Medicine on July 6, 2026, led by a team including researchers at Mayo Clinic in Arizona, with collaborators at the University of Pennsylvania in the United States and Mansoura University in Egypt, assembles the current evidence on sepsis-associated atrial fibrillation, abbreviated SAAF. The review examines how often the arrhythmia occurs, which patients are most vulnerable, how it is detected and diagnosed, and how it is currently managed, before laying out the research agenda needed to close the remaining gaps. The corresponding author, Sameh Hozayen, MB, BCh, of the Division of Hospital Internal Medicine at Mayo Clinic in Arizona, describes the condition as sitting in a clinical blind spot: common, dangerous, and treated without a map. The stated aim of the review is to bring existing evidence together in one place and to define precisely what still needs to be learned so that these patients can receive standardized, evidence-based care rather than ad hoc, institution-by-institution improvisation.

The clinical stakes are considerable. Unlike primary atrial fibrillation, which arises without a clear acute trigger and is supported by decades of randomized trial data and established treatment guidelines, SAAF develops in response to the acute stress of critical illness. In many patients it resolves once the underlying infection is brought under control, which has historically encouraged the assumption that it is a transient and relatively benign companion to sepsis. The review makes clear that this assumption is untenable. Sepsis-associated atrial fibrillation is associated with a 4.6-fold increase in stroke risk and a 1.7-fold increase in in-hospital mortality compared with sepsis patients who never develop the arrhythmia. Recurrence is common, affecting up to half of patients within five years, and survivors carry elevated risks of heart failure, stroke, and death that persist long after they have been discharged from the hospital and the acute infection has been cured.

Part of what makes SAAF so difficult to manage is that its causes are fundamentally multifactorial. The review traces a convergence of mechanisms: systemic inflammation driven by the septic response, autonomic dysfunction that disrupts the neural regulation of heart rate, direct myocardial injury, hemodynamic stress from fluctuating blood pressure and fluid shifts, and electrolyte disturbances that destabilize the electrical properties of the atria. Each of these forces alone can promote arrhythmia; together, in a critically ill patient, they create an environment in which the heart’s upper chambers are pushed toward disorganized electrical activity. This mechanistic complexity also explains why the arrhythmia’s course tracks so closely with the trajectory of the underlying illness, waxing and waning as the infection, the inflammatory response, and the patient’s hemodynamic status evolve hour by hour.

That volatility would be challenging enough on its own, but the therapeutic landscape is complicated by a more fundamental problem: no randomized studies have compared management strategies specifically in this population. Clinicians are therefore forced to extrapolate from trials conducted in patients with primary atrial fibrillation, an imperfect fit for critically ill patients whose physiology can shift dramatically within hours and whose organ dysfunction alters drug metabolism, tolerance, and risk. The review is explicit that this extrapolation, while unavoidable in current practice, leaves every major treatment decision shadowed by uncertainty, and that acknowledging that uncertainty is the first step toward designing the studies that will eventually resolve it.

The uncertainties begin with the simplest question: how fast should the heart be allowed to beat? For rate control, beta-blockers appear superior to alternative agents in observational data, but no randomized trial has confirmed which approach is genuinely best in septic patients, who may tolerate beta-blockade poorly when blood pressure is fragile. For rhythm control, electrical cardioversion can restore normal sinus rhythm, yet it frequently fails to hold while the underlying illness persists, because the same inflammatory, autonomic, and metabolic forces that triggered the arrhythmia remain active and quickly reassert themselves. Choosing between accepting a rapid rhythm and repeatedly attempting to restore sinus rhythm is, at present, a matter of clinical judgment rather than evidence.

The thorniest question of all is anticoagulation, the use of blood-thinning medication to prevent the clots that cause stroke in atrial fibrillation. Critically ill patients with sepsis face simultaneous and opposing risks: dangerous clotting on one side and dangerous bleeding on the other. Standard stroke-risk prediction tools used to guide anticoagulation in primary atrial fibrillation have not been validated in the sepsis setting, so the usual calculus for deciding who should be treated does not reliably apply. In observational studies, anticoagulation has not clearly reduced stroke risk in these patients—and in one multicenter cohort it actually increased bleeding—leading many clinicians to defer it. The review stresses that deferral or initiation must be individualized to each patient’s phase of illness, weighing the evolving clotting and bleeding risks as sepsis progresses or resolves, rather than applying a fixed rule.

Against this backdrop of uncertainty, the review distills the field’s needs into concrete research priorities. The authors call for a universally accepted definition of sepsis-associated atrial fibrillation, without which studies cannot be compared or pooled; validated prediction models to identify high-risk patients early in their illness; prospective randomized trials comparing rate control and rhythm control strategies; clearer, evidence-based anticoagulation strategies tailored to the phases of sepsis; and standardized rhythm monitoring after discharge to capture recurrence and long-term outcomes that are currently invisible to follow-up care. The authors also underscore the economic dimension of the problem: SAAF adds roughly 9,000 dollars in charges per patient, a substantial burden multiplied across the millions of sepsis admissions worldwide each year. Emerging technologies may help close the detection gap, and the review points to growing roles for artificial intelligence in predicting and detecting the arrhythmia in real time, potentially flagging high-risk patients before the rhythm deteriorates.

Until dedicated trials are completed and the research priorities are fulfilled, the authors conclude, the management of sepsis-associated atrial fibrillation will remain a matter of careful, individualized judgment. The central message for clinicians is to treat the whole critically ill patient rather than the arrhythmia in isolation: controlling the infection, correcting electrolyte disturbances, supporting hemodynamics, and reassessing rhythm and anticoagulation decisions continuously as the patient’s condition changes. For researchers, the message is equally direct. A condition that affects as many as one in five sepsis patients, multiplies stroke risk nearly fivefold, and drives measurable excess mortality and cost can no longer be managed on borrowed evidence from a different disease. The review’s roadmap—definition, prediction, randomized comparison of treatments, rational anticoagulation, and structured follow-up—offers the first coordinated plan for turning a clinical blind spot into standardized, evidence-based care.

Subject of Research: Sepsis-associated atrial fibrillation: incidence, risks, diagnosis, and management

Article Title: Atrial fibrillation during sepsis: what clinicians know—and what remains unclear

Article References: Atrial fibrillation during sepsis: what clinicians know—and what remains unclear. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: atrial fibrillation, sepsis, critical care, stroke risk, anticoagulation, rate control, rhythm control, intensive care medicine, arrhythmia, clinical review, artificial intelligence, research priorities